Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism - 11/09/11
Abstract |
The diagnosis of hypoglycemia caused by hyperinsulinism may be difficult because insulin levels are not uniformly elevated at the time of hypoglycemia. Insulin-like growth factor binding protein-1 (IGFBP-1) is a 28 kd protein whose secretion is acutely inhibited by insulin. We hypothesized that serum levels of IGFBP-1 would be a useful marker of hyperinsulinism. We measured IGFBP-1 levels during the course of standardized fasting studies in hospitalized children; 36 patients became hypoglycemic during the fasting studies, and samples obtained at the point of hypoglycemia were analyzed. On the basis of the currently used diagnostic criteria, 13 children had hyperinsulinism, 16 had ketotic hypoglycemia or no disorder, 3 had hypopituitarism or isolated growth hormone deficiency, 2 had glycogen storage disease type I, and 2 had fatty acid oxidation disorders. In control subjects (children with ketotic hypoglycemia or no disorder), IGFBP-1 levels rose during fasting to a mean of 343.8 ± 71.3 ng/ml in the sample drawn at the time of hypoglycemia. Mean IGFBP-1 levels at hypoglycemia for the entire group with hyperinsulinism were 52.4 ± 11.5 ng/ml, significantly different from levels seen in control subjects (p < 0.0001). In children with moderately controlled hyperinsulinism (fasting tolerance >4 hours), mean IGFBP-1 levels at the time of hypoglycemia were 71.5 ± 16.9 ng/ml. IGFBP-1 levels in the children with poorly controlled hyperinsulinism (fasting tolerance <4 hours) failed to rise during fasting, with a mean of 30.1 ± 10.4 ng/ml in the final sample. IGFBP-1 levels were inversely correlated with serum insulin and C-peptide levels (r = –0.71 and –0.72, respectively; p < 0.0001). Patients with other endocrinologic or metabolic diseases that result in fasting hypoglycemia demonstrated a rise in IGFBP-1 levels similar to that seen in ketotic hypoglycemia. Low serum levels of IGFBP-1 at the time of hypoglycemia provide an additional marker of insulin action that might help to differentiate hyperinsulinism from other hypoglycemic disorders. (J Pediatr 1997;131:193-9)
Le texte complet de cet article est disponible en PDF.Abbreviations : IGF, IGFBP-1
Plan
| a Recipient of the Society for Pediatric Research Fellow’s Clinical Research Award for this presentation. |
|
| Supported in part by U.S. Food and Drug Association grant FD-R 001181-01 (Dr. Cohen), National Institutes of Health grant RR-00240 (Drs. Baker and Stanley), an American Diabetes Association Career Development Award (Dr. Cohen), and a Lawson Wilkins Pediatric Endocrine Society Serono Fellowship (Dr. Levitt Katz). |
|
| Reprint requests: Lorraine E. L. Katz, MD, Assistant Professor of Pediatrics, Children’s Hospital of Philadelphia, Division of Endocrinology, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104. |
|
| 0022-3476/97/$5.00 + 0 9/21/79490 |
Vol 131 - N° 2
P. 193-199 - août 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
